Coya Therapeutics, Inc.
COYACoya Therapeutics is a clinical-stage biotechnology company focused on developing proprietary therapies that enhance the function of regulatory T cells (Tregs) to treat chronic inflammatory and neurodegenerative diseases.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Coya Therapeutics is a clinical-stage biotechnology company focused on developing proprietary therapies that enhance the function of regulatory T cells (Tregs) to treat chronic inflammatory and neurodegenerative diseases. The company leverages multiple therapeutic modalities, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, to restore immune homeostasis. Its primary value proposition lies in its 'Pipeline in a Product' approach, specifically targeting conditions like ALS, Frontotemporal Dementia, and Alzheimer's Disease.
Coya positions itself as a leader in multi-pathway Treg modulation, differentiating from monotherapy competitors by combining Treg expansion with effector cell suppression.
Questions, answered.
- What is Coya Therapeutics, Inc.'s market cap?
- Coya Therapeutics, Inc. (COYA) has a market capitalization of $99.7M and trades on NASDAQ.
- Who are Coya Therapeutics, Inc.'s competitors?
- Coya Therapeutics, Inc.'s key competitors include Nektar Therapeutics, Kyverna Therapeutics, Amgen, and others. These companies compete in similar markets and product categories.
- Who does Coya Therapeutics, Inc. partner with?
- Coya Therapeutics, Inc.'s notable partners include Dr. Reddy's Laboratories, Houston Methodist Hospital, Carnegie Mellon University, and others.
- Where is Coya Therapeutics, Inc. headquartered?
- Coya Therapeutics, Inc. is headquartered in United States of America and employs approximately 6 people. It has been publicly traded since 2022.